Loyal, the San Francisco biotech pursuing the first FDA-approved drug to extend lifespan in any species, had its safety package for LOY-002 accepted by the agency in January — the milestone that triggers the formal review clock [1].

LOY-002 is a daily oral pill for dogs aged 10 and older, weighing at least 14 pounds. The drug targets insulin-like growth factor 1 — IGF-1 — a hormone associated with accelerated aging in large-breed dogs [1]. Larger dogs age faster than smaller ones, partly because of sustained IGF-1 elevation, and Loyal's hypothesis is that moderating that signal can extend healthy lifespan.

No drug has ever been approved by any regulatory agency for the explicit purpose of extending lifespan in any species, human or animal [2]. LOY-002 would be the first. The FDA has created a new conditional approval pathway — the Reasonably Expected to Produce Clinical Benefit framework — to accommodate drugs targeting aging, which is not classified as a disease under existing regulatory categories.

The manufacturing data submission is expected in 2027, which sets the conditional approval timeline at late 2027 at the earliest [1]. Loyal has two additional drugs in development: one for large-dog cardiac longevity and one targeting a different aging pathway.

The longevity research community watches the dog pipeline closely. Dogs share environments with humans, experience similar late-life diseases, and have a lifespan short enough to generate clinical data in tractable timeframes. A proven canine aging drug validates the biological targets before a human trial begins.

-- NORA WHITFIELD, Chicago